Skip to content
DataLookout
Menu

NCT06592612

Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment

StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

progression-free survival, PFS
Timeframe: From date of treatment beginning until the date of follow-up completion, up to 2 year.

Secondary (3)

objective response rate,ORR
overall survival, OS
Incidence of adverse events (safety )

Arms and interventions

Control ArmActive comparator

Patients in the control arm will receive second-line systemic therapy until disease progression is confirmed by imaging or until they are unable to continue systemic therapy due to adverse events. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.

SBRT ArmExperimental

Patients in the SBRT arm will also receive second-line systemic therapy until disease progression is confirmed by imaging or until they are unable to continue systemic therapy due to adverse events. The choice and stipulations for second-line systemic therapy drugs are the same as those for the control arm. SBRT will be administered to all oligoprogressive lesions and must begin within 2 weeks after the start of second-line therapy. Systemic therapy will not be paused during SBRT. Patients who do not withdraw from the study will not receive crossover treatment; however, if a patient in the control group withdraws from the study due to tumor progression and is assessed as suitable for SBRT, salvage SBRT will be administered promptly.

Radiation: SBRT and second-line systemic therapy

Drugs: Second-line systemic therapy